Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains

Mehrdad Falamarzi Askarani, Fei Fang, Scott Counts, Liangliang SunPROTEOMICS 2025 · DOI

TL;DR

This study introduces a novel quantitative top-down proteomics (TDP) approach combining capillary zone electrophoresis (CZE) with mass spectrometry (MS/MS) to analyze human brain proteoforms. They discovered significant differences in protein variants (proteoforms) between healthy and Alzheimer's disease (AD) brains, highlighting the complexity of AD pathogenesis and identifying potential biomarkers.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by cognitive decline and the aggregation of specific proteins like amyloid-beta and tau. Understanding the molecular mechanisms driving AD progression is crucial for developing effective diagnostics and therapies. Traditional proteomics methods (bottom-up proteomics) often lose information about protein variants (proteoforms) due to enzymatic digestion. Proteoforms, arising from alternative splicing, post-translational modifications (PTMs), and other processes, can have distinct biological functions. Therefore, a method that can accurately identify and quantify these intact proteoforms in complex biological samples like the human brain is needed to gain a deeper understanding of AD.

Methods

The researchers developed a two-dimensional (2D) analytical workflow. First, they employed Size Exclusion Chromatography (SEC) to fractionate complex brain tissue lysates based on molecular weight, reducing sample complexity and improving proteome coverage. Following SEC, they utilized Capillary Zone Electrophoresis (CZE) coupled with Tandem Mass Spectrometry (MS/MS) for proteoform identification and quantification. CZE acts as a liquid-phase ion mobility separation technique, separating analytes based on their mobility in an electric field, which is influenced by their mass-to-charge ratio. This CZE-MS/MS approach allows for the analysis of intact proteoforms. The data analysis was performed using the TopPIC pipeline, a specialized software for top-down proteomics, to identify and quantify proteoforms and their abundance differences between AD and control samples.

Datasets

The study analyzed postmortem temporal cortex tissue samples from a small cohort of 5 Alzheimer's disease (AD) patients and 5 age-matched healthy controls. These samples were obtained from the Michigan Alzheimer's Disease Research Center (MADRC) clinical cohort.

Key Insights and Ideas

  • Proteoform Heterogeneity is Key: The study strongly suggests that focusing on individual proteoforms, rather than just proteins, is essential for understanding complex diseases like AD. The drastic differences observed at the proteoform level between AD and healthy brains underscore this point.
  • CZE-MS/MS as a Powerful Tool: The successful application of CZE-MS/MS for quantitative TDP in human brain tissue demonstrates its potential as a robust platform for analyzing complex proteomes, offering high separation efficiency.
  • Bidirectional Regulation of Key AD Genes: The identification of proteoforms from genes known to be involved in AD (e.g., CALM1, MAPT, NRGN) exhibiting opposite expression patterns (upregulated in AD vs. healthy) highlights the intricate regulatory mechanisms at play in disease progression.
  • PTMs as Critical Modifiers: The study identified numerous proteoforms with various post-translational modifications (PTMs) like acetylation, phosphorylation, and oxidation, emphasizing their role in altering protein function and contributing to AD pathology.

Key Results

  • 3191 Unique Proteoforms Identified: The CZE-MS/MS approach successfully identified a substantial number of unique proteoforms (3191) from 500 proteins.
  • Drastic Proteoform Transformation: A significant transformation in the proteoform profile was observed in AD brains compared to healthy controls. Only 736 out of 3191 proteoforms (23%) were common to both groups, with over 2200 proteoforms being unique to either AD or healthy samples.
  • 157 Differentially Abundant Proteoforms: Among the shared proteoforms, 157 showed statistically significant abundance differences between AD and control groups.
  • Biological Pathway Enrichment: Gene Ontology and pathway analysis of the differentially expressed proteoforms revealed broad changes in biological processes in AD brains, including telomere organization, substantia nigra development, amyloid fibril formation, and microtubule cytoskeleton organization, all highly relevant to AD pathogenesis.
  • Specific Proteoform Examples: The study highlighted specific proteoforms, such as those from tau (MAPT), neurogranin (NRGN), and calmodulin-1 (CALM1), showing distinct expression patterns and PTMs in AD. For instance, certain tau proteoforms were found to be condition-specific, and others showed significantly higher abundance in AD.

Limitations and Future Work

  • Small Sample Size: The authors acknowledge that a main limitation of this pilot study is the small number of human brain samples analyzed (5 AD and 5 controls).
  • Future Expansion: To address this, they plan to expand the study to include more human brain samples, encompassing control, early AD, and potentially late AD subjects. This larger cohort will allow for more robust statistical analysis and a deeper understanding of the proteoform landscape in AD progression.
  • Further Functional Studies: While the study identifies potential proteoform biomarkers and therapeutic targets, further functional studies will be necessary to elucidate the precise roles of these specific proteoforms and their PTM combinations in AD pathogenesis.

Summary updated

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and pathological protein aggregation. Comprehensive quantitative proteomics of brain tissues from AD patients is critical for pursuing a better understanding of the molecular mechanisms that drive AD progression. Here, we present one of the first quantitative top-down proteomics (TDP) studies of postmortem cortex samples from AD patients and healthy controls to profile their proteoform differences by coupling capillary zone electrophoresis (CZE, liquid-phase ion mobility) to tandem mass spectrometry (MS/MS). We identified 3191 unique proteoforms and uncovered a drastic transformation in the proteoform profile in AD compared to healthy controls. Over 2200 proteoforms were exclusively identified in either AD or healthy control samples, and 157 proteoforms identified in both AD and control samples showed statistically significant abundance differences between the two conditions. Gene Ontology and pathway analysis of the genes associated with those proteoforms revealed broad changes in biological processes in AD brains, for example, telomere organization, substantia nigra development, amyloid fibril formation, microtubule cytoskeleton organization, progressive neurological disorders, long-term synaptic potentiation, and axogenesis. These biological processes are highly associated with the development of AD. Our study revealed a pool of potential novel proteoform biomarkers of AD in human brain samples for early diagnosis and therapy development. SUMMARY: Alzheimer's disease (AD) is a chronic neurodegenerative disease, destroying brain cells and causing thinking ability and memory to decline over time. Proteins (e.g., amyloid and tau) play key roles in the development of AD. Global and accurate protein measurement of human brains of AD patients and healthy controls will shed new light on the molecular mechanisms driving AD progression and discover new biomarkers for AD diagnosis and therapeutic development. Here, we performed the first CZE-MS/MS-based quantitative top-down proteomics (TDP) of a small cohort of AD human brain samples and healthy controls (5 AD and 5 control) to determine the differentially quantified proteoforms between the two health conditions. Over 3000 proteoforms were identified, and only about 700 proteoforms were detected in both conditions, indicating drastically different proteoform profiles between the two conditions. The differentially quantified proteoforms (e.g., tau, neurogranin, and calmodulin-1 proteoforms) are associated with biological processes relevant to AD development, for example, amyloid fibril formation, microtubule disruption, synaptic transmission, and axogenesis. The results offer a deep view of the proteoform transformation in the AD human brain compared to the healthy control, providing potential proteoform biomarkers for AD diagnosis and proteoform targets for therapeutic development.
BibTeX
@inproceedings{askarani2025coupling,
  author = {Mehrdad Falamarzi Askarani and Fei Fang and Scott Counts and Liangliang Sun},
  title = {{Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains}},
  booktitle = {PROTEOMICS},
  year = {2025},
  doi = {10.1002/pmic.70041},
}
Figure